Genmab, a global biotech company specializing in antibody-based cancer therapies, initiated a share buy-back program worth DKK 725 million. This program, running from February 18 to March 31, 2026, aims to cover obligations under its Restricted Stock Unit scheme and manage share dilution. The company plans to repurchase up to 342,130 shares, adding to its existing treasury shares.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Genmab Launches DKK 725 Million Share Buy-Back to Cover RSU Commitments
Genmab, a global biotech company specializing in antibody-based cancer therapies, initiated a share buy-back program worth DKK 725 million. This program, running from February 18 to March 31, 2026, aims to cover obligations under its Restricted Stock Unit scheme and manage share dilution. The company plans to repurchase up to 342,130 shares, adding to its existing treasury shares.